PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.86%
Revenue growth above 1.5x ADI's 4.17%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
7.84%
Gross profit growth similar to ADI's 7.59%. Walter Schloss would assume both firms track common industry trends.
55.61%
EBIT growth above 1.5x ADI's 16.12%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
50.63%
Operating income growth above 1.5x ADI's 16.12%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
68.30%
Net income growth above 1.5x ADI's 16.87%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
65.22%
EPS growth above 1.5x ADI's 17.02%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
72.73%
Diluted EPS growth above 1.5x ADI's 15.22%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.26%
Share reduction while ADI is at 0.11%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.94%
Reduced diluted shares while ADI is at 0.13%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.26%
Dividend growth under 50% of ADI's 20.00%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
50.33%
OCF growth above 1.5x ADI's 5.19%. David Dodd would confirm a clear edge in underlying cash generation.
52.89%
FCF growth above 1.5x ADI's 3.32%. David Dodd would verify if the firm’s strategic investments yield superior returns.
157.09%
10Y revenue/share CAGR above 1.5x ADI's 99.70%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
22.78%
5Y revenue/share CAGR above 1.5x ADI's 11.67%. David Dodd would look for consistent product or market expansions fueling outperformance.
50.86%
3Y revenue/share CAGR 1.25-1.5x ADI's 38.91%. Bruce Berkowitz might see better product or regional expansions than the competitor.
190.70%
10Y OCF/share CAGR under 50% of ADI's 1011.86%. Michael Burry would worry about a persistent underperformance in cash creation.
-5.25%
Negative 5Y OCF/share CAGR while ADI is at 4.81%. Joel Greenblatt would question the firm’s operational model or cost structure.
34.69%
3Y OCF/share CAGR under 50% of ADI's 190.46%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
682.46%
Net income/share CAGR at 50-75% of ADI's 1280.76%. Martin Whitman might question if the firm’s product or cost base lags behind.
-7.84%
Negative 5Y net income/share CAGR while ADI is 43.84%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
90.65%
Below 50% of ADI's 207.47%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
63.47%
10Y equity/share CAGR in line with ADI's 64.99%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
22.37%
5Y equity/share CAGR at 50-75% of ADI's 41.78%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
34.60%
3Y equity/share CAGR at 50-75% of ADI's 58.42%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
643.71%
Dividend/share CAGR of 643.71% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
113.74%
5Y dividend/share CAGR above 1.5x ADI's 66.14%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
55.92%
3Y dividend/share CAGR 1.25-1.5x ADI's 50.15%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
10.22%
AR growth well above ADI's 9.37%. Michael Burry fears inflated revenue or higher default risk in the near future.
1.73%
Inventory growth well above ADI's 2.21%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.44%
Negative asset growth while ADI invests at 2.55%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
1.05%
50-75% of ADI's 2.04%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-11.01%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.70%
Our R&D shrinks while ADI invests at 2.54%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.30%
We cut SG&A while ADI invests at 0.96%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.